Glaukos Corp
$ 108.85
1.29%
04 Dec - close price
- Market Cap 6,171,937,000 USD
- Current Price $ 108.85
- High / Low $ 110.02 / 107.30
- Stock P/E N/A
- Book Value 13.41
- EPS -1.54
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.12 %
- 52 Week High 163.71
- 52 Week Low 73.16
About
Glaukos Corporation (GKOS), headquartered in San Clemente, California, is a leading innovator in ophthalmic medical technology and pharmaceuticals, dedicated to developing cutting-edge treatments for glaucoma, corneal disorders, and retinal diseases. The company is renowned for its expertise in minimally invasive surgical techniques and advanced drug delivery systems, which have substantially enhanced patient outcomes and quality of life. With a strong focus on research and development, Glaukos is strategically positioned to meet the rising demand for effective ophthalmic therapies, reinforcing its role as a key player in the industry and in the global fight against blindness and vision impairment.
Analyst Target Price
$120.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-07-30 | 2025-04-29 | 2025-02-19 | 2024-11-04 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 | 2023-08-02 | 2023-05-03 | 2023-02-22 |
| Reported EPS | -0.16 | -0.24 | -0.22 | -0.4 | -0.28 | -0.52 | -0.7 | -0.63 | -0.5 | -0.55 | -0.59 | -0.53 |
| Estimated EPS | -0.2586 | -0.26 | -0.3556 | -0.3885 | -0.48 | -0.51 | -0.57 | -0.55 | -0.55 | -0.55 | -0.58 | -0.55 |
| Surprise | 0.0986 | 0.02 | 0.1356 | -0.0115 | 0.2 | -0.01 | -0.13 | -0.08 | 0.05 | 0 | -0.01 | 0.02 |
| Surprise Percentage | 38.1284% | 7.6923% | 38.1327% | -2.9601% | 41.6667% | -1.9608% | -22.807% | -14.5455% | 9.0909% | 0% | -1.7241% | 3.6364% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GKOS
2025-10-20 14:22:00
The U.S. Food and Drug Administration has approved Glaukos Corp's new eye therapy, Epioxa, for treating keratoconus. This approval provides a less painful treatment option that does not require the removal of the corneal epithelium, a key advantage over their earlier therapy. Epioxa is expected to be commercially available in Q1 2026 and could accelerate adoption among new doctors due to its improved approach.
2025-10-18 21:23:52
This retrospective study evaluated the three-year outcomes of combined phacoemulsification and iStent inject W implantation in Japanese eyes with primary open-angle glaucoma (POAG), including a high prevalence of normal-tension glaucoma (NTG). The study found significant and sustained reductions in intraocular pressure (IOP) and medication burden, with minimal complications, supporting the safety and effectiveness of this procedure in NTG-predominant populations. These favorable results, consistent with international studies, suggest iStent inject W is a viable treatment option for advanced glaucoma cases in this demographic.
2025-10-18 11:44:02
This article provides an AI-driven analysis of Glaukos Corporation (NASDAQ: GKOS), highlighting mixed sentiment and a mid-channel oscillation pattern. It outlines three distinct institutional trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths and support/resistance levels for GKOS.
2025-10-17 15:34:49
Valitor has announced the appointment of Gregory D. Kunst, a biotech and ophthalmic industry veteran, as its new Chief Executive Officer. Mr. Kunst brings a wealth of experience from his previous leadership roles at companies such as Glaukos Corporation and Alcon, where he was instrumental in significant product launches and revenue growth. This strategic appointment is expected to drive Valitor's continued growth and innovation in the biotech sector.
2025-10-15 07:04:21
Glaukos Corporation announced its technologies will be featured at the 2025 American Academy of Ophthalmology (AAO) annual meeting. The company will present scientific programming on its iDose TR investigational device for glaucoma and other corneal health innovations. Key presentations will highlight long-term data on iDose TR's ability to reduce IOP-lowering medication burden and its outcomes when used with cataract surgery.
2025-10-14 19:49:30
This article provides an earnings call transcript for Glaukos' Q2 2025 results, highlighting record sales and a subsequent rise in stock value. However, an application error prevented the full content of the transcript from loading.
